Premium
Haemoconcentration of residual cardiopulmonary bypass blood using Hemosep ® : a randomised controlled trial
Author(s) -
Hogan M.,
Needham A.,
Ortmann E.,
Bottrill F.,
Collier T. J.,
Besser M. W.,
Klein A. A.
Publication year - 2015
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/anae.13019
Subject(s) - autotransfusion , cardiopulmonary bypass , medicine , anesthesia , dose , cardiac surgery , blood transfusion , surgery , cardiology
Summary Cardiac surgery and cardiopulmonary bypass are associated with haemodilution, activation of haemostasis and blood transfusion. We undertook a randomised controlled trial that included 53 patients in order to compare autotransfusion of residual cardiopulmonary bypass blood with residual blood concentrated using the novel Hemosep ® device. There was no difference in patients' mean ( SD ) haemoglobin concentration after autotransfusion of unprocessed blood compared with Hemosep; 103.5 (10.2) g.l −1 vs 106.2 (12.4) g.l −1 , respectively, p = 0.40. The mean ( SD ) change in haemoglobin concentration after autotransfusion was 5.9 (5.3) g.l −1 in the control group compared with 4.9 (6.3) g.l −1 in the Hemosep group, p = 0.545. Adjusted for baseline haemoglobin concentrations, the estimated mean (95% CI) difference in change in haemoglobin concentration (control vs Hemosep) was 0.57 (−2.65 to 3.79) g.l −1 , p = 0.72. This was despite Hemosep's reducing the weight of the blood from a mean ( SD ) of 778.7 (243.0) g to 607.3 (248.2) g, p < 0.001. The haemoglobin concentration in the processed blood increased from a mean ( SD ) of 87.0 (15.1) g.l −1 to 103.7 (17.4) g.l −1 , p < 0.001. We conclude that Hemosep is capable of haemoconcentration when employed to process residual cardiopulmonary bypass blood, but that this is insufficient to increase patient haemoglobin.